|
| 37042063 | LC-MS/MS method for the quantitation of a dual PI3K/BRD4 inhibitor SF2523 in mouse plasma: Application to plasma protein binding and metabolism studies. | Biomed Chromatogr | 2023 |
| 35390226 | PI3K-α/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron. | Clin Transl Med | 2022 |
| 35716662 | Binding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection. | Structure | 2022 |
| 33480647 | Augmented Antitumor Activity for Novel Dual PI3K/BDR4 Inhibitors, SF2523 and SF1126 in Ewing Sarcoma. | J Pediatr Hematol Oncol | 2021 |
| 33688653 | Blockade of SARS-CoV-2 infection in vitro by highly potent PI3K-α/mTOR/BRD4 inhibitor. | bioRxiv | 2021 |
| 34926269 | Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia. | Front Oncol | 2021 |
| 34557659 | The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma. | iScience | 2021 |
| 33391502 | COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. | Theranostics | 2021 |
| 32694708 | Design of thienopyranone-based BET inhibitors that bind multiple synthetic lethality targets. | Sci Rep | 2020 |
| 31974273 | Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. | Mol Cancer Ther | 2020 |
| 32793389 | A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity. | Cell Discov | 2020 |
| 32927667 | Amino Acids Regulate Cisplatin Insensitivity in Neuroblastoma. | Cancers (Basel) | 2020 |
| 30853982 | Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System. | J Oncol | 2019 |
| 30071568 | Erratum to: Vascular Permeability and Remodelling Coincide with Inflammatory and Reparative Processes after Joint Bleeding in Factor VIII-Deficient Mice. | Thromb Haemost | 2019 |
| 31511835 | Hypoxia-induced PIM kinase and laminin-activated integrin α6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC. | Am J Clin Exp Urol | 2019 |
| 31539380 | Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma. | PLoS One | 2019 |
| 31018997 | SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer. | Mol Cancer Ther | 2019 |
| 29475942 | Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication. | J Biol Chem | 2018 |
| 29847841 | Vascular Permeability and Remodelling Coincide with Inflammatory and Reparative Processes after Joint Bleeding in Factor VIII-Deficient Mice. | Thromb Haemost | 2018 |
| 28817691 | Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotype. | PLoS One | 2017 |
| 28139703 | The differential ability of asparagine and glutamine in promoting the closed/active enzyme conformation rationalizes the Wolinella succinogenes L-asparaginase substrate specificity. | Sci Rep | 2017 |
| 28137841 | Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. | Proc Natl Acad Sci U S A | 2017 |
| 26938241 | PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. | PLoS One | 2016 |
| 28881723 | Association of high microvessel α<sub>v</sub>β<sub>3</sub> and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. | Oncotarget | 2016 |
| 27496136 | Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. | Mol Cancer Ther | 2016 |
| 25578041 | Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma. | Cancer Chemother Pharmacol | 2015 |
| 26473951 | Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release. | PLoS One | 2015 |
| 26257191 | Vascular remodeling underlies rebleeding in hemophilic arthropathy. | Am J Hematol | 2015 |
| 24162827 | PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression. | J Neurooncol | 2014 |
| 25425962 | Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12)â¿¿V-Ha-Ras transgenic mouse glioma model. | Cancer Cell Int | 2014 |
| 24982421 | MDM2 regulates hypoxic hypoxia-inducible factor 1α stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner. | J Biol Chem | 2014 |
| 25103499 | A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis. | Mol Cancer Res | 2014 |
| 24770346 | Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo. | PLoS One | 2014 |
| 24886428 | A PKC-SHP1 signaling axis desensitizes Fcγ receptor signaling by reducing the tyrosine phosphorylation of CBL and regulates FcγR mediated phagocytosis. | BMC Immunol | 2014 |
| 24881819 | PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment. | Exp Cell Res | 2014 |
| 24309609 | Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. | J Pediatr Hematol Oncol | 2014 |
| 23045271 | Distinct roles for fibroblast growth factor signaling in cerebellar development and medulloblastoma. | Oncogene | 2013 |
| 23410005 | Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors. | J Med Chem | 2013 |
| 23355037 | An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo. | Cancer Chemother Pharmacol | 2013 |
| 22921184 | Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. | Eur J Cancer | 2012 |
| 20972874 | The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. | Cancer Chemother Pharmacol | 2011 |
| 19636556 | In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. | Cancer Chemother Pharmacol | 2010 |
| 20520772 | Heterozygosity for Pten promotes tumorigenesis in a mouse model of medulloblastoma. | PLoS One | 2010 |
| 19276385 | Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. | Cancer Res | 2009 |
| 19939254 | PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. | BMC Cancer | 2009 |
| 19411066 | Regulation of XIAP translation and induction by MDM2 following irradiation. | Cancer Cell | 2009 |
| 19199965 | PI-3 kinase-PTEN signaling node: an intercept point for the control of angiogenesis. | Curr Pharm Des | 2009 |
| 18172313 | A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. | Cancer Res | 2008 |
| 18339867 | The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. | Cancer Res | 2008 |
| 17213812 | A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth. | Oncogene | 2007 |